Enhancing HER2-low breast cancer detection with quantitative transcriptomics
Accurate identification of HER2-low breast cancers remains challenging using standard IHC. We analyzed 3182 breast tumors using transcriptomics, revealing detectable ERBB2 mRNA in 86% of IHC 0 cases. Pathological complete response was most prevalent in anti-HER2-treated patients with highest ERBB2 expression. Our results demonstrate that transcriptomics can sensitively detect HER2 expression and stratify patients beyond IHC classification, supporting its use as a complementary biomarker for guiding anti-HER2 therapy decisions.
Authors
- Maria-Anna Misiakou (ORCID: https://orcid.org/0000-0002-9965-4164)
- Maj‐Britt Jensen (ORCID: https://orcid.org/0000-0001-5348-3040)
- Maria Rossing (ORCID: https://orcid.org/0000-0003-4325-3027)
- Bent Ejlertsen
- Maj-Lis Møller Talman
Institutions
- University of Copenhagen (DK)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- Danish Breast Cancer Cooperative Group (DK)
Publication Details
- Journal
- npj Breast Cancer
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1038/s41523-025-00817-9
- Citations
- 2
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 2.09